Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Depreciation and Depletion (2020 - 2025)

Maravai Lifesciences Holdings has reported Depreciation and Depletion over the past 6 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Depreciation and Depletion at $6.0 million for Q4 2025, up 8.36% from a year ago — trailing twelve months through Dec 2025 was $23.6 million (up 12.92% YoY), and the annual figure for FY2025 was $23.6 million, up 12.92%.
  • Depreciation and Depletion for Q4 2025 was $6.0 million at Maravai Lifesciences Holdings, roughly flat from $6.0 million in the prior quarter.
  • Over the last five years, Depreciation and Depletion for MRVI hit a ceiling of $6.0 million in Q3 2025 and a floor of $1.3 million in Q1 2021.
  • Median Depreciation and Depletion over the past 5 years was $3.4 million (2023), compared with a mean of $3.6 million.
  • Biggest five-year swings in Depreciation and Depletion: decreased 25.72% in 2021 and later skyrocketed 130.1% in 2024.
  • Maravai Lifesciences Holdings' Depreciation and Depletion stood at $1.7 million in 2021, then increased by 12.44% to $2.0 million in 2022, then soared by 100.41% to $3.9 million in 2023, then surged by 40.23% to $5.5 million in 2024, then increased by 8.36% to $6.0 million in 2025.
  • The last three reported values for Depreciation and Depletion were $6.0 million (Q4 2025), $6.0 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.